Prevnar Full Dose Schedule Restored By CDC
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Disease Control & Prevention reinstates four-dose recommendation for Wyeth’s pneumococcal conjugate vaccine. CDC recommended deferring the third and fourth doses earlier this year because of ongoing supply problems.
You may also be interested in...
Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth
Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.
Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth
Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.
Prevnar Recommendation Will Be Restored “Very Soon”
The Centers for Disease Control & Prevention is on track to reinstate normal dosing recommendations for the pneumococcal conjugate vaccine Prevnar in the near future, Wyeth CEO Robert Essner indicated during the Bear Stearns meeting Sept. 14.